LGI1-antibody associated epilepsy successfully treated in the outpatient setting

Simple item page
dc.catalogadorjlo
dc.contributor.authorUribe-San-Martín, R.
dc.contributor.authorCiampi, E.
dc.contributor.authorSantibañez, R.
dc.contributor.authorIrani, S. R.
dc.contributor.authorMárquez, A.
dc.contributor.authorCruz, J. P.
dc.contributor.authorSoler, B.
dc.contributor.authorMiranda, M. C.
dc.contributor.authorHenríquez, M.
dc.contributor.authorCárcamo, C.
dc.date.accessioned2024-01-19T15:29:25Z
dc.date.available2024-01-19T15:29:25Z
dc.date.issued2020
dc.description.abstractWe report six patients with anti-LGI1 associated epilepsy. Two patients presented with new-onset generalized tonic-clonic seizures, four developed faciobrachial dystonic seizures and two piloerection. All patients had significant cognitive complaints at the time of diagnosis. All patients described seizure reduction during the first week of carbamazepine, and seizure freedom was obtained at a median of 13 days (range 7–22), sustained after the initiation of immunosuppression. Median time from symptom onset to carbamazepine initiation was 164 days (range 38–206 days). We discuss the particular seizure response to sodium channel blocking antiepileptic drugs, alone or associated with immunosuppression in this antibody mediated seizures.
dc.fuente.origenORCID-ene24
dc.identifier.doi10.1016/j.jneuroim.2020.577268
dc.identifier.issn0165-5728
dc.identifier.urihttp://dx.doi.org/10.1016/j.jneuroim.2020.577268
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/80756
dc.information.autorucEscuela de Medicina; Uribe San Martín, Reinaldo Moisés; 0000-0002-3422-7962; 127201
dc.information.autorucEscuela de Medicina; Ciampi Diaz, Ethel Leslie; 0000-0002-7330-5433; 132794
dc.information.autorucEscuela de Medicina; Santibáñez Ávila, Rodrigo Andrés; 0000-0002-2391-4468; 149895
dc.information.autorucEscuela de Medicina; Cruz Quiroga, Juan Pablo; 0000-0002-7524-7273; 17836
dc.information.autorucEscuela de Medicina; Soler León, Bernardita María; 0000-0002-8143-4497; 189547
dc.information.autorucEscuela de Medicina; Henríquez Baeza, Marco Antonio; S/I; 1015584
dc.information.autorucEscuela de Medicina; Carcamo Rodriguez Claudia Andrea; 0000-0002-9430-216X; 562
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final6
dc.pagina.inicio1
dc.revistaJournal of Neuroimmunology
dc.rightsacceso restringido
dc.subjectLeucine-rich glioma-inactivated 1 (LGI1)
dc.subjectAutoantibodies
dc.subjectAntibody mediated seizures
dc.subjectAutoimmune epilepsy
dc.subjectCarbamazepine
dc.subjectNeuroimmunology
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleLGI1-antibody associated epilepsy successfully treated in the outpatient setting
dc.typeartículo
dc.volumen345
sipa.codpersvinculados127201
sipa.codpersvinculados132794
sipa.codpersvinculados149895
sipa.codpersvinculados17836
sipa.codpersvinculados189547
sipa.codpersvinculados1015584
sipa.codpersvinculados562
sipa.trazabilidadORCID;2024-01-08
Files
Collections
Artículos de revistas